The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Adalat LA 20 mg Prolonged-Release Tablet

milligram(s) Prolonged-release tablet

Bayer LimitedPA1410/025/005

Main Information

Trade NameAdalat LA 20 mg Prolonged-Release Tablet
Active SubstancesNifedipine
Dosage FormProlonged-release tablet
Licence HolderBayer Limited
Licence NumberPA1410/025/005

Group Information

ATC CodeC08CA Dihydropyridine derivatives
C08CA05 nifedipine


Licence Issued04/03/1999
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back